| __timestamp | Iovance Biotherapeutics, Inc. | Perrigo Company plc |
|---|---|---|
| Wednesday, January 1, 2014 | 9335772 | 675200000 |
| Thursday, January 1, 2015 | 12390000 | 771800000 |
| Friday, January 1, 2016 | 25602000 | 1205500000 |
| Sunday, January 1, 2017 | 21262000 | 1146500000 |
| Monday, January 1, 2018 | 28430000 | 1125800000 |
| Tuesday, January 1, 2019 | 40849000 | 1166100000 |
| Wednesday, January 1, 2020 | 60210000 | 1175500000 |
| Friday, January 1, 2021 | 83664000 | 1111400000 |
| Saturday, January 1, 2022 | 104097000 | 1210100000 |
| Sunday, January 1, 2023 | 106916000 | 1274600000 |
Unveiling the hidden dimensions of data
In the ever-evolving landscape of the pharmaceutical and biotechnology sectors, understanding the financial health of companies is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Perrigo Company plc and Iovance Biotherapeutics, Inc. from 2014 to 2023. Perrigo, a global consumer self-care company, consistently reported higher SG&A expenses, peaking at approximately $1.27 billion in 2023. This represents a steady increase of about 89% from 2014. In contrast, Iovance, a pioneering biotech firm, saw its SG&A expenses grow by over 1,000% during the same period, reaching around $107 million in 2023. This stark contrast highlights the differing scales and growth trajectories of these companies. As the industry continues to innovate, tracking such financial metrics offers valuable insights into strategic priorities and operational efficiencies.
Cost Management Insights: SG&A Expenses for Pfizer Inc. and Iovance Biotherapeutics, Inc.
SG&A Efficiency Analysis: Comparing Takeda Pharmaceutical Company Limited and Perrigo Company plc
Selling, General, and Administrative Costs: Teva Pharmaceutical Industries Limited vs Perrigo Company plc
Who Optimizes SG&A Costs Better? United Therapeutics Corporation or Iovance Biotherapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Genmab A/S and Iovance Biotherapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Incyte Corporation and Perrigo Company plc
Operational Costs Compared: SG&A Analysis of Alkermes plc and Iovance Biotherapeutics, Inc.
Selling, General, and Administrative Costs: ADMA Biologics, Inc. vs Iovance Biotherapeutics, Inc.
PTC Therapeutics, Inc. vs Perrigo Company plc: SG&A Expense Trends
Perrigo Company plc or Amphastar Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Catalyst Pharmaceuticals, Inc. vs Iovance Biotherapeutics, Inc.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Iovance Biotherapeutics, Inc. and MannKind Corporation